BIOCHEMICAL DERANGEMENTS RELATED TO METABOLIC SYNDROME IN EPILEPTIC PATIENTS ON TREATMENT WITH VALPROIC ACID

Valproate (VPA), a branched chain fatty acid, is a broad spectrum anticonvulsant used for the treatment of epilepsy such as generalized and partial seizures [1]. Continuous administration of antiepileptic drugs results in long standing complications such as psychiatric disorders, metabolic disorder, endocrine disorders, idiosyncratic reactions and drug interaction effects in some cases [2]. Valproate is metabolized in the liver by glucuronidation process and to a lesser extent by β oxidation. [3].

0